Cargando…

Advances in treating premature ejaculation

In spite of its high prevalence and long history, the ambiguity regarding the definition, epidemiology and management of premature ejaculation continues. Topical anesthetic creams and daily or on-demand selective serotonin reuptake inhibitor (SSRI) treatment forms the basis of pharmacotherapy for pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Çayan, Selahittin, Şerefoğlu, Ege Can
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Faculty of 1000 Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108949/
https://www.ncbi.nlm.nih.gov/pubmed/25184045
http://dx.doi.org/10.12703/P6-55
_version_ 1782327815008419840
author Çayan, Selahittin
Şerefoğlu, Ege Can
author_facet Çayan, Selahittin
Şerefoğlu, Ege Can
author_sort Çayan, Selahittin
collection PubMed
description In spite of its high prevalence and long history, the ambiguity regarding the definition, epidemiology and management of premature ejaculation continues. Topical anesthetic creams and daily or on-demand selective serotonin reuptake inhibitor (SSRI) treatment forms the basis of pharmacotherapy for premature ejaculation today, in spite of low adherence by patients. Psychotherapy may improve the outcomes when combined with these treatment modalities. Tramadol and phosphodiesterase type 5 inhibitors have a limited role in the management of premature ejaculation. Further research is required to develop better options for the treatment of this common sexual disorder.
format Online
Article
Text
id pubmed-4108949
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Faculty of 1000 Ltd
record_format MEDLINE/PubMed
spelling pubmed-41089492014-09-02 Advances in treating premature ejaculation Çayan, Selahittin Şerefoğlu, Ege Can F1000Prime Rep Review Article In spite of its high prevalence and long history, the ambiguity regarding the definition, epidemiology and management of premature ejaculation continues. Topical anesthetic creams and daily or on-demand selective serotonin reuptake inhibitor (SSRI) treatment forms the basis of pharmacotherapy for premature ejaculation today, in spite of low adherence by patients. Psychotherapy may improve the outcomes when combined with these treatment modalities. Tramadol and phosphodiesterase type 5 inhibitors have a limited role in the management of premature ejaculation. Further research is required to develop better options for the treatment of this common sexual disorder. Faculty of 1000 Ltd 2014-07-08 /pmc/articles/PMC4108949/ /pubmed/25184045 http://dx.doi.org/10.12703/P6-55 Text en © 2014 Faculty of 1000 Ltd http://creativecommons.org/licenses/by-nc/3.0/legalcode All F1000Prime Reports articles are distributed under the terms of the Creative Commons Attribution-Non Commercial License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Çayan, Selahittin
Şerefoğlu, Ege Can
Advances in treating premature ejaculation
title Advances in treating premature ejaculation
title_full Advances in treating premature ejaculation
title_fullStr Advances in treating premature ejaculation
title_full_unstemmed Advances in treating premature ejaculation
title_short Advances in treating premature ejaculation
title_sort advances in treating premature ejaculation
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108949/
https://www.ncbi.nlm.nih.gov/pubmed/25184045
http://dx.doi.org/10.12703/P6-55
work_keys_str_mv AT cayanselahittin advancesintreatingprematureejaculation
AT serefogluegecan advancesintreatingprematureejaculation